Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001213900-24-029053
Filing Date
2024-04-02
Accepted
2024-04-02 07:12:25
Documents
17
Period of Report
2024-02-13
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 2 TO FORM 8-K ea0201955-8ka2_cerother.htm   iXBRL 8-K/A 51711
2 CONSOLIDATED FINANCIAL STATEMENTS OF CERO FOR THE YEARS ENDED DECEMBER 31, 2023 ea020195502ex99-1_cerother.htm EX-99.1 229277
3 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION OF THE COMPANY FOR ea020195502ex99-2_cerother.htm EX-99.2 273477
4 MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERA ea020195502ex99-3_cerother.htm EX-99.3 97770
  Complete submission text file 0001213900-24-029053.txt   979036

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE cero-20240213.xsd EX-101.SCH 3818
6 XBRL DEFINITION FILE cero-20240213_def.xml EX-101.DEF 28779
7 XBRL LABEL FILE cero-20240213_lab.xml EX-101.LAB 38680
8 XBRL PRESENTATION FILE cero-20240213_pre.xml EX-101.PRE 26988
20 EXTRACTED XBRL INSTANCE DOCUMENT ea0201955-8ka2_cerother_htm.xml XML 8040
Mailing Address 201 HASKINS WAY SUITE 230 SOUTH SAN FRANCISCO CA 94080
Business Address 201 HASKINS WAY SUITE 230 SOUTH SAN FRANCISCO CA 94080 650-407-2376
CERO THERAPEUTICS HOLDINGS, INC. (Filer) CIK: 0001870404 (see all company filings)

EIN.: 871088814 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-40877 | Film No.: 24812202
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)